Aker Biomarine AS

Aker Biomarine AS

AKBM · OL · Consumer Defensive / Packaged Foods

133.20NOK-0.20 (-0.15%)

Price History

Full chart

Market Stats

Previous Close133.40
Open133.40
Day Range130.80 – 133.40
52-Week Range78.80 – 136.40
Volume3.47K
Market Cap10.70B
P/E (TTM)0.00
Forward P/E57.14
EPS-1.16
Dividend Yield0.00%
Beta0.33
50-Day Avg122.34
200-Day Avg106.41

About

Aker BioMarine ASA, a biotech innovator, develops and supplies krill-derived products for consumer health and wellness worldwide. It operates through three segments: Human Health Ingredients (HHI), Consumer Health Products, and Emerging Business. The Human Health Ingredients segment sells B2B krill oil supplements for humans under the Superba Krill brand; supplements for brain health under the LYSOVETA brand; and marine-origin DHA omega-3 from microalgae under the Revervia brand name, as well as advanced phospholipid technology under PL+ name. The Consumer Health Products segment sells processed and packaged krill, fish, and plants derived raw materials to retailers in the United States. The Emerging Business segment offers krill oil under Kori brand name. The company provides protein solutions under the Understory brand; biostimulants under KRBNX brand; and a therapeutic candidate based on omega-3 to manage and treat cardiometabolic diseases under CaPre brand name, as well as delivers circular products utilizing recycled industrial and marine plastic waste under AION name. Aker BioMarine ASA was founded in 2006 and is headquartered in Lysaker, Norway. Aker BioMarine ASA is a subsidiary of Aker Capital Newco As.

Company Details

  • SectorConsumer Defensive
  • IndustryPackaged Foods
  • CEOMr. Matts Johansen
  • Employees258
  • HeadquartersOksenøyveien 10, Lysaker, Norway, 1327, Norway
  • Websitehttps://www.akerbiomarine.com

Leadership

  • Mr. Matts JohansenChief Executive Officer · b. 1976
  • Ms. Katrine Mourud KlavenessChief Financial Officer · b. 1977
  • Ms. Marte DalseggExecutive VP of People & Communications
  • Mr. Trond Atle SmedsrudChief Executive Officer of Emerging Business
  • Mr. Simon SewardChief Executive Officer of Human Health Ingredients
  • Mr. Seth FrenchChief Executive Officer of Lang Pharma Nutrition Inc

Financials

Income Statement

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue74.05M12.19M25.02M52.05M55.29M84.00M108.99M112.30M105.12M116.74M125.54M154.18M246.17M288.59M262.06M277.20M335.30M199.00M218.10M
Growth (%)--83.54%+105.27%+108.02%+6.22%+51.94%+29.75%+3.03%-6.39%+11.05%+7.54%+22.82%+59.66%+17.23%-9.19%+5.78%+20.96%-40.65%+9.60%
Cost of Revenue40.79M1.29M10.87M12.93M16.59M46.39M93.68M80.26M56.75M51.16M75.39M89.93M150.89M179.01M174.00M162.40M222.40M129.90M120.30M
Gross Profit33.26M10.90M14.15M39.12M38.70M37.61M15.31M32.04M48.37M65.57M50.15M64.25M95.28M109.58M88.06M114.80M112.90M69.10M97.80M
Gross Margin44.91%89.41%56.55%75.16%70.00%44.78%14.05%28.53%46.01%56.17%39.94%41.67%38.70%37.97%33.60%41.41%33.67%34.72%44.84%
Operating Expense60.64M37.72M56.77M52.39M48.08M43.88M18.28M43.60M38.56M49.38M51.48M54.00M96.94M91.11M82.22M92.70M107.60M75.60M85.00M
Operating Income-27.38M-26.82M-42.62M-13.27M-9.38M-6.27M-2.96M-11.57M9.81M16.19M-1.34M10.26M-1.67M18.47M5.84M22.10M5.30M-6.50M12.80M
Operating Margin-36.97%-220.00%-170.34%-25.49%-16.97%-7.46%-2.72%-10.30%9.33%13.87%-1.07%6.65%-0.68%6.40%2.23%7.97%1.58%-3.27%5.87%
EBITDA20.95M23.23M-13.98M-2.21M502.61K19.52M11.85M6.45M25.34M32.59M15.06M33.84M36.40M67.67M59.30M81.90M49.70M36.60M32.80M
EBITDA Margin28.29%190.59%-55.86%-4.25%0.91%23.24%10.88%5.75%24.10%27.92%12.00%21.95%14.79%23.45%22.63%29.55%14.82%18.39%15.04%
Net Income-29.22M-61.81M-52.46M28.92M-18.93M-11.82M46.59M-17.26M805.00K-2.06M-17.77M-1.02M-23.75M-5.46M-8.01M10.00M-9.00M180.30M-25.50M
Net Income Margin-39.45%-507.06%-209.66%55.56%-34.24%-14.07%42.75%-15.37%0.77%-1.76%-14.15%-0.66%-9.65%-1.89%-3.06%3.61%-2.68%90.60%-11.69%
R&D-------8.90M2.10M3.50M-9.07M5.40M3.90M2.96M4.00M690.00K4.29M500.00K
R&D as % of Total Revenue-------7.93%2.00%3.00%-5.88%2.20%1.35%1.13%1.44%0.21%2.16%0.23%
Interest Expense16.91M53.06M20.88M17.69M9.55M14.87M-----12.26M22.79M18.74M13.68M20.30M33.40M2.50M13.90M
Interest Expense % of Total Revenue22.83%435.29%83.45%33.99%17.27%17.70%-----7.95%9.26%6.49%5.22%7.32%9.96%1.26%6.37%

Balance Sheet

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets374.13M275.92M279.73M291.55M312.96M373.62M400.41M255.16M258.42M279.34M377.41M430.25M692.22M700.43M757.49M822.40M827.10M387.40M384.90M
Total Liabilities210.58M204.21M245.90M78.93M119.12M141.50M148.18M179.90M182.26M205.32M318.12M251.43M537.68M327.26M387.12M443.70M460.60M213.50M241.00M
Total Equity163.54M71.70M33.82M212.62M193.84M232.13M229.68M75.26M76.16M74.03M59.30M178.81M154.55M373.17M370.37M378.80M366.60M173.50M143.90M
Cash64.13M31.55M1.38M14.29M2.18M895.55K6.91M2.41M2.75M3.51M-1.53M12.43M9.09M9.15M21.00M25.40M15.00M16.40M
Total Debt187.25M182.84M235.03M69.06M106.89M117.85M148.18M157.00M158.31M172.00M-205.37M420.06M242.80M324.84M381.20M393.00M147.50M-
Net Debt123.12M151.29M233.65M54.77M104.71M116.96M141.26M154.60M155.55M168.49M-203.84M407.64M233.71M315.69M360.20M367.60M132.50M162.90M

Cash Flow

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-40.43M-38.72M-33.13M-20.75M2.51M5.37M--11.13M18.27M20.88M9.17M7.89M12.31M-51.04M729.00K15.10M47.40M12.20M4.20M
Investing Cash Flow-24.44M-19.79M-13.63M-31.81M-48.92M-58.21M--14.36M-21.95M-10.90M-111.30M-64.54M-175.95M-2.05M-79.21M-56.40M-48.90M379.40M-17.00M
Financing Cash Flow-20.76M39.87M10.35M65.66M34.51M51.40M-21.10M4.02M-9.23M101.33M56.45M174.73M50.16M78.94M52.50M6.70M-404.00M14.60M
Capital Expenditure37.67M50.19M13.63M2.89M36.36M43.52M012.04M17.42M10.79M111.20M64.51M126.92M23.71M81.11M46.10M49.30M17.40M9.10M
Free Cash Flow-78.10M-88.91M-46.76M-23.64M-33.84M-38.15M--23.18M847.00K10.09M--56.62M-114.61M-74.75M-80.38M-31.00M-1.90M-5.20M-4.90M
Dividends Paid-----------------373.20M0
FCF to OCF193.18%229.63%141.15%113.93%-1346.67%-710.00%-208.16%4.64%48.33%--717.23%-931.25%146.45%-11025.79%-205.30%-4.01%-42.62%-116.67%
Dividend Paid to FCF------------------7176.92%0.00%

Earnings

Report DateJul 15, 2020Oct 29, 2020Feb 16, 2021Apr 28, 2021Jul 14, 2021Oct 29, 2021Feb 17, 2022Apr 29, 2022Jul 14, 2022Nov 1, 2022Feb 14, 2023May 10, 2023Jul 14, 2023Nov 1, 2023Mar 20, 2024Apr 26, 2024Jul 12, 2024Nov 1, 2024Mar 31, 2025Apr 23, 2025Jul 11, 2025Oct 31, 2025Feb 12, 2026Apr 30, 2026Jul 10, 2026Oct 29, 2026
EPS Estimate-0.110.70-0.110.04-0.08-0.15-0.15-0.040.060.05-0.080.040.040.03-0.040.03-0.01-0.020.000.010.030.040.040.07
EPS Actual-1.040.080.17-0.10-0.040.18-0.09-0.100.100.050.02-0.17-0.030.020.08-1.430.110.09-0.08-0.39-1.730.03-0.040.01-0.01-
Surprise--27.27%-75.71%9.09%-200.00%325.00%40.00%33.33%350.00%-16.67%-60.00%-112.50%-175.00%-50.00%166.67%-175.00%200.00%-700.00%-1856.50%-43260.00%134.69%-233.33%-75.00%-125.00%-
TimingPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-market-After-hoursPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap10.70B
Enterprise Value12.99B
Trailing P/E0.00
Forward P/E57.14
Price / Sales47.11
Price / Book8.76
EPS-1.16
Book Value15.46
Revenue (TTM)227.20M
Gross Profit (TTM)102.30M
EBITDA23.20M
Profit Margin-5.85%
Operating Margin5.01%
Return on Equity-7.01%
Return on Assets2.34%
Shares Outstanding87.72M
Shares Float7.81M
Beta0.33
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20241×
45.00Sep 9, 2024